JLE

Virologie

MENU

Influenza virus epidemiology: a permanent vaccine challenge Volume 23, issue 5, Septembre-Octobre 2019

  • [1] https://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/
  • [2] https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-national/bulletin-epidemiologique-grippe-semaine-9.-saison-2016-2017
  • [3] https://www.who.int/influenza/gisrs_laboratory/updates/summaryreport/en/
  • [4] Mosnier A., Caini S., Daviaud I. Clinical characteristics are similar across type A and B influenza virus infections. PLoS One. 2015;10:e0136186. 9
  • [5] Belongia E.A., Simpson M.D., King J.P. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16:942-951. 8
  • [6] Schild G.C., Oxford J.S., de Jong J.C., Webster R.G. Evidence for host-cell selection of influenza virus antigenic variants. Nature. 1983;303:706-709.
  • [7] Zost S.J., Parkhouse K., Gumina M.E. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A. 2017;114:12578-12583. 47
  • [8] Houser K., Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015;17:295-300. 3